Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, providing tailored funding solutions to advance life sciences innovation. The company partners with academic institutions, biotech, and pharmaceutical firms, holding a diverse portfolio of market-leading therapies. Royalty Pharma is publicly traded on Nasdaq (RPRX) and is known for its significant global market share and contributions to the biopharma ecosystem.
Recent Transactions involving Royalty Pharma
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma |
Blueprint Medicines |
Sixth StreetRoyalty Pharma |
Biotechnology Research | |
|
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →